EFSA is gathering the views of stakeholders in the early stages of our scientific assessment on the welfare of animals during transport in the EU. The assessment will support the European Commission’s current review of animal welfare legislation.
Clean Sky’s Highlights 2020 report outlines our key achievements during this extraordinary year, from our technology developments to participation figures to the Technology Evaluator.
Working with nature and enhancing the role of ecosystems can help reduce the impacts of climate change and increase climate change resilience. Such an approach can deliver multiple benefits, including lowering pressures on biodiversity, improving human health and well-being, reducing greenhouse gas emissions and building a sustainable economy, according to a European Environment Agency (EEA) […]
Train travel remains overall the most environmentally friendly mode of motorised passenger transport in Europe — in terms of greenhouse gas emissions — as compared to travelling by car or plane, according to two transport and environment studies published by the European Environment Agency (EEA) today.
Finland’s guarantee in favour of the airline Finnair to help it obtain a loan of €600 million from a pension fund to cover its working capital requirements following the Covid-19 pandemic is compatible with EU law
Aid measures introduced by Sweden and Denmark for SAS for damage resulting from the cancellation or rescheduling of flights in the wake of travel restrictions caused by the Covid-19 pandemic comply with EU law
EMA continues to monitor very rare blood clots with low blood platelets that occurred after vaccination with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).
As announced last week, EMA’s safety committee (PRAC) is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen’s COVID-19 vaccine. The type of blood clot reported, cerebral venous sinus thrombosis (CVST), occurred in most cases in combination with low levels of blood platelets (thrombocytopenia).
Credit terms and conditions slightly eased for all counterparty types except hedge funds, while hedge fund use of financial leverage increased Maximum maturity of funding increased for many types of collateral, while haircuts and financing rates/spreads decreased for funding secured by all types of collateral Demand for funding continued to weaken across all collateral types […]
ECHA recommends for the European Commission to add seven substances, including the cyclosiloxanes D4, D5 and D6, to the Authorisation List. Once on the list, companies will need to apply for authorisation to continue using them.